Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro

Translational Research

Volumn 164, Issue 2, 2014, Pages 158-168

  Rathore, Kusum ^a   Alexander, Mary ^a   Cekanova, Maria ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

AB; AB1010; Abbreviations; canine oral squamous cell carcinoma; Cel; Celecoxib; COX; cyclooxygenase; EGFR; epidermal growth factor receptor; feline oral squamous cell carcinoma; FeOSCC; hSCC; human transitional cell carcinoma; ICC; immunocytochemistry; K9OSCC; Masitinib; nonsteroidal anti inflammatory drug; NSAID; oral squamous cell carcinoma; OSCC; PDGFR; Piro; Piroxicam; platelet derived growth factor receptor; receptor tyrosine kinase; RTK; vascular endothelial growth factor receptor; VEGFR

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MASITINIB; PIROXICAM; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P27; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CARCINOMA CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CATS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOGS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MOUTH NEOPLASMS; PIROXICAM; PROTEIN KINASE INHIBITORS; THIAZOLES;

EID: 84904788338     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.02.002     Document Type: Article

References (38)

1. C.K. Martin, W.P. Dirksen, and S.T. Shu et al. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma Oral Oncol 48 2012 491 499
2. L. DiBernardi, M. Dore, and J.A. Davis et al. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment Prostaglandins Leukot Essent Fatty Acids 76 2007 245 250 (Pubitemid 46590012)
3. P.A. Boria, D.J. Murry, and P.F. Bennett et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs J Am Vet Med Assoc 224 2004 388 394 (Pubitemid 38140261)
4. E.B. Stelow, and S.E. Mills Squamous cell carcinoma variants of the upper aerodigestive tract Am J Clin Pathol 124 2005 S96 109
5. Oral cancer facts. Newport Beach, Calif: The Oral Cancer Foundation 2013, www.oralcancerfoundation.org.
6. Wypij JM. A naturally occurring feline model of head and neck squamous cell carcinoma. Pathol Res Int. 2013, Article ID 502197, 1-7.
7. J.S. Reif, C. Bruns, and K.S. Lower Cancer of the nasal cavity and paranasal sinuses and exposure to environmental tobacco smoke in pet dogs Am J Epidemiol 147 1998 488 492 (Pubitemid 28146109)
8. S.H. O'Neill, K.M. Newkirk, E.A. Anis, R. Brahmbhatt, L.A. Frank, and S.A. Kania Detection of human papillomavirus DNA in feline premalignant and invasive squamous cell carcinoma Vet Dermatol 22 2011 68 74
9. P.K. Nicholls, B.A. Klaunberg, and R.A. Moore et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection Virology 265 1999 365 374 (Pubitemid 30022230)
10. E.G. MacEwen Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment Cancer Metastasis Rev 9 1990 125 136
11. W. Xia, Y.K. Lau, and H.Z. Zhang et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members Clin Cancer Res 5 1999 4164 4174 (Pubitemid 30013801)
12. A.N. Al-Dissi, D.M. Haines, B. Singh, and B.A. Kidney Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas Vet Pathol 44 2007 823 830 (Pubitemid 350260702)
13. D.L. Wheeler, E.F. Dunn, and P.M. Harari Understanding resistance to EGFR inhibitors: impact on future treatment strategies Nat Rev Clin Oncol 7 2010 493 507
14. A.J. Dannenberg, S.M. Lippman, J.R. Mann, K. Subbaramaiah, and R.N. DuBois Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention J Clin Oncol 23 2005 254 266 (Pubitemid 46206877)
15. D.W. Tang, S.C. Lin, K.W. Chang, C.W. Chi, C.S. Chang, and T.Y. Liu Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma: evidence for COX-2 induction by areca quid ingredients in oral keratinocytes J Oral Pathol Med 32 2003 522 529
16. E.M. Pestili de Almeida, C. Piche, J. Sirois, and M. Dore Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs J Histochem Cytochem 49 2001 867 875 (Pubitemid 32565980)
17. A. Hayes, T. Scase, J. Miller, S. Murphy, A. Sparkes, and V. Adams COX-1 and COX-2 expression in feline oral squamous cell carcinoma J Comp Pathol 135 2006 93 99 (Pubitemid 44424278)
18. P. Dubreuil, S. Letard, and M. Ciufolini et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS One 4 2009 e7258
19. K.A. Hahn, G. Ogilvie, and T. Rusk et al. Masitinib is safe and effective for the treatment of canine mast cell tumors J Vet Intern Med 22 2008 1301 1309
20. B.R. Schmidt, N.W. Glickman, D.B. DeNicola, A.E. de Gortari, and D.W. Knapp Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs J Am Vet Med Assoc 218 2001 1783 1786 (Pubitemid 32520131)
21. M. Cekanova, M.J. Uddin, and J.W. Bartges et al. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo Cancer Prev Res 6 2013 466 476
22. J.G. Rheinwald, and M.A. Beckett Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas Cancer Res 41 1981 1657 1663 (Pubitemid 11114553)
23. B.A. Teicher, S.A. Holden, and M.J. Kelley et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II) Cancer Res 47 1987 388 393 (Pubitemid 17009596)
24. M. Komhoff, Y. Guan, and H.W. Shappell et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas Am J Pathol 157 2000 29 35 (Pubitemid 30641721)
25. M. Paoloni, and C. Khanna Translation of new cancer treatments from pet dogs to humans Nat Rev Cancer 8 2008 147 156 (Pubitemid 351161319)
26. D.W. Knapp, and D.J. Waters Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans Mol Med Today 3 1997 8 11 (Pubitemid 28091878)
27. S.P. Lerner, M.P. Schoenberg, and C.N. Sternberg Textbook of bladder cancer 2006 Taylor and Francis United Kingdom
28. V.J. Poirier, B. Kaser-Hotz, D.M. Vail, and R.C. Straw Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma Vet Radiol Ultrasound 54 2013 81 88
29. J.J. Marretta, L.D. Garrett, and S.M. Marretta Feline oral squamous cell carcinoma: an overview Vet Med 102 2007 392 406 (Pubitemid 47168154)
30. K.E. Stebbins, C.C. Morse, and M.H. Goldschmidt Feline oral neoplasia: a ten-year survey Vet Pathol 26 1989 121 128
31. S.M. Cohen, and S.J. Lippard Cisplatin: from DNA damage to cancer chemotherapy Prog Nucl Acid Res Mol Biol 67 2001 93 130 (Pubitemid 33804642)
32. P. Uribe, and S. Gonzalez Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy Pathol Res Pract 207 2011 337 342
33. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther 315 2005 971 979 (Pubitemid 41635382)
34. F.M. Johnson, P. Yang, R.A. Newman, and N.J. Donato Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by Imatinib mesylate J Exp Ther Oncol 4 2004 317 325 (Pubitemid 40189444)
35. X.M. Xu, L. Sansores-Garcia, X.M. Chen, N. Matijevic-Aleksic, M. Du, and K.K. Wu Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate Proc Natl Acad Sci U S A 96 1999 5292 5297 (Pubitemid 29214576)
36. E. Kopp, and S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
37. Z. Dong, C. Huang, R.E. Brown, and W.Y. Ma Inhibition of activator protein 1 activity and neoplastic transformation by aspirin J Biol Chem 272 1997 9962 9970 (Pubitemid 27171667)
38. V.C. Allport, D.M. Slater, R. Newton, and P.R. Bennett NF-κB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH) Mol Hum Reprod 6 2000 561 565 (Pubitemid 30365803)